---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-232252"
form_type: "8-K"
ticker: null
cik: "0001496323"
company_name: "IGM Biosciences, Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:25:10.075842+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# IGM Biosciences pivots to autoimmunity, ends aplitabart work, names new CEO Mary Beth Harler

## Summary
- Strategic pivot to focus exclusively on T cell engagers for autoimmune diseases; aplitabart and other oncology programs minimized.
- Mary Beth Harler, M.D. appointed CEO and director effective Sept 30, 2024; Fred Schwarzer resigns as CEO and director.
- Bruce Keyt, Ph.D. steps down as CSO; Chris Takimoto, M.D., Ph.D. resigns as CMO effective Oct 1, 2024.
- Cash runway extended into 2027; reduction in force expected; activities substantially complete by Q1 2025.
- Imvotamab (CD20xCD3) ongoing in RA, SLE, myositis; IGM-2644 (CD38xCD3) expected to enter clinic for gMG by end of 2024.

## SEC filing metadata
- accession: 0001193125-24-232252
- form_type: 8-K
- cik: 0001496323
- company_name: IGM Biosciences, Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/d860501d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-232252
- JSON: https://secwatch.observer/filing/0001193125-24-232252.json
- Plain text: https://secwatch.observer/filing/0001193125-24-232252.txt

## Key facts
- Executive change
  Mary Beth Harler, M.D. was appointed as Chief Executive Officer and Director at IGM Biosciences, Inc..
  - Action: appointed
  - Role: Chief Executive Officer and Director
  source text: Mary Beth Harler, M.D. has been appointed as the Company’s Chief Executive Officer, effective as of the Effective Date, and as a member of the Board (initial term ending at the annual stockholder meeting in 2025), effective as of October 1, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm
- Executive change
  Fred Schwarzer resigned as Chief Executive Officer, President and Director at IGM Biosciences, Inc..
  - Action: resigned
  - Role: Chief Executive Officer, President and Director
  source text: In connection with the Strategic Pivot, Fred Schwarzer resigned as Chief Executive Officer, President and a member of the board of directors (the “Board”) of the Company, effective as of September 30, 2024 (the “Effective Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1496323/000119312524232252/0001193125-24-232252-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.